Therapy Areas: Vaccines
Sanofi's Nuvaxovid demonstrates superior tolerability to Moderna's mNEXSPIKE in phase 4 study
20 April 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Saturday that its protein-based COVID-19 vaccine, Nuvaxovid (NVX-CoV2705), showed statistically sig...
hVIVO signs influenza human challenge trial agreement with Traws Pharma
14 April 2026 - hVIVO plc (AIM:HVO), a specialist in conducting human challenge trials, announced on Tuesday that it has signed a clinical trial agreement with Traws Pharma (NASDAQ:TRAW), a clinical-s...
Delonix Bioworks launches Phase 1 trial of next-generation MenB OMV vaccine DX-104
31 March 2026 - Delonix Bioworks, a clinical-stage biotechnology company developing genetically engineered bacterial vaccines, announced on Monday the initiation of first-in-human (FIH) dosing in a Ph...
GC Biopharma secures first Latin American approval for BARYCELA Inj.
...
Clover Biopharmaceuticals reports positive US Phase I data for RSV re-vaccination in older adults
25 March 2026 - Commercial-stage biotechnology company Clover Biopharmaceuticals Ltd (HKEX:02197) on Tuesday reported additional positive data from a Phase I clinical trial in the United States evalua...
Pfizer and Valneva report strong Phase 3 results for Lyme disease vaccine candidate
23 March 2026 - US biopharmaceutical company Pfizer Inc (NYSE:PFE) and French vaccine company Valneva SE (Nasdaq:VALN) (Euronext Paris:VLA) on Monday reported positive topline results from the Phase 3...